{
  "extraction_metadata": {
    "timestamp": "2025-10-01T15:31:47.244456",
    "source_type": "clinical_guideline",
    "indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
    "total_countries": 11,
    "temperature": 0.3
  },
  "outcomes_by_country": {
    "AT": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "AT",
      "Outcomes": "overall survival, progression-free survival, objective response rate (mRECIST), objective response rate (RECIST 1.1), time to radiologic progression, partial response, intraoperative complications, mortality, morbidity, adverse events, neurotoxicity, time to progression of the tumor, time to deterioration, EORTC QLQ-C30, EQ-5D-5L",
      "ChunksUsed": 20,
      "ContextTokens": 4473
    },
    "BE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "BE",
      "Outcomes": "objective response, survival, recurrence, pain, fever, liver failure, portal vein thrombosis, adverse events (general), Karnofsky index, disease-free survival, quality of life",
      "ChunksUsed": 20,
      "ContextTokens": 3954
    },
    "DE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "DE",
      "Outcomes": "overall survival, progression-free survival, time to progression of the tumor, objective response (mRECIST), objective response (RECIST 1.1), partial response, adverse events (general), intraoperative complications, neurotoxicity, EORTC QLQ-C30, EQ-5D-5L, SF-36, visual analogue scale",
      "ChunksUsed": 20,
      "ContextTokens": 4473
    },
    "DK": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "DK",
      "Outcomes": "overall survival, progression-free survival, tumour response, disease-free survival, local tumour control, perioperative mortality, morbidity, leukaemia, postoperative softening, gallbladder abscess, complications (general), recurrence, quality of life, quality of life (SIRT-treated patients compared to sorafenib-treated patients)",
      "ChunksUsed": 20,
      "ContextTokens": 3965
    },
    "ES": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "ES",
      "Outcomes": "survival, prognosis (BCLC staging system), adverse events, liver function status, overall medical condition",
      "ChunksUsed": 20,
      "ContextTokens": 3354
    },
    "EU": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "EU",
      "Outcomes": "bleeding, tumour seeding",
      "ChunksUsed": 14,
      "ContextTokens": 2774
    },
    "FR": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "FR",
      "Outcomes": "time-to-progression, toxicity, survival, response rates (RECIST criteria), adverse events, diarrhoea, fatigue, nausea, neutropenia, EORTC QLQ-C30, EORTC QLQ-LC13, EQ-5D-5L",
      "ChunksUsed": 20,
      "ContextTokens": 4523
    },
    "IT": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "IT",
      "Outcomes": "improved survival, recurrence rate, disease progression, mortality not related to hepatocellular carcinoma, complication rate, adverse events, liver-related morbidity, rebleeding, response rates, early diagnosis, cost-effectiveness, false positives, alpha-fetoprotein, upper abdominal ultrasound, imaging method (low-contrast positive imaging), pathologic diagnosis, donor morbidity, recipient deaths, down-staging, complete response",
      "ChunksUsed": 20,
      "ContextTokens": 4050
    },
    "NL": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "NL",
      "Outcomes": "overall survival, progression-free survivorship, response rate, local recurrence, disease-free survivorship, local tumor control, bridge to transplant, adverse events, complications, adverse events (grade 3 and higher or serious/major adverse events), adverse events (grade â‰¥ 3), quality of life, quality of life (measured with a validated and reliable instrument), Functional Assessment of Cancer Therapy (FACT-G), FACT-Hepatobiliary (FACT-Hep), EQ-5D, EQ-VAS",
      "ChunksUsed": 20,
      "ContextTokens": 3549
    },
    "PO": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "PO",
      "Outcomes": "overall survival, time to progression, perioperative mortality, annual mortality, adverse events, liver function (Child-Pugh scale), tumour response (mRECIST test), tumour response (RECIST criteria), imaging assessment (multiphase computed tomography with contrast), imaging assessment (magnetic resonance imaging), imaging assessment (ultrasonography), histopathological diagnosis, pathomorphological evaluation",
      "ChunksUsed": 17,
      "ContextTokens": 2605
    },
    "SE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "SE",
      "Outcomes": "survival, prognosis, quality of life, EORTC QLQ-30, FACT-G, EORTC QLQ-HCC18, FACT-Hep, pain, complications, local recurrence, reintervention, adverse events, liver function, tumour response (RECIST criteria), tumour response (modified RECIST criteria, mRECIST), tumour response (LR-TR criteria: viable, equivocal, nonviable), general condition, comorbidity",
      "ChunksUsed": 20,
      "ContextTokens": 3303
    }
  }
}